

CURRICULUM VITAE

CHRISTOPHER A. FAUSEL, Pharm.D. MHA BCOP

January 2016

Home address:

5411 North Capitol Avenue
Indianapolis, Indiana 46208
(317) 840-2849

Office address:

Indiana University Simon Cancer Center C2324
1030 West Michigan Street
Indianapolis, Indiana 46202-5277
Phone: (317) 948-6866
Fax: (317) 948-4989
Pager: (317) 312-6356
E-mail: cfausel@iuhealth.org

Education:

Graduate:

Masters of Health Administration, January 2011 – May 2013. Simmons College, Boston, Massachusetts (with honors).

Pharmacy Leadership Academy, American Society of Health-System Pharmacists. January 2011 – April 2012.

Doctor of Pharmacy. September 1994 - June 1996. Albany College of Pharmacy, Albany, New York.

Undergraduate:

B.S. Pharmacy. September 1988 - May 1993. Albany College of Pharmacy, Albany, New York.

Work Experience:

January 2011 – present.

Clinical Manager, Oncology Pharmacy
Indiana University Health
Indianapolis, Indiana.

Dr. Reddy's Laboratories, Ltd., et al.

v.

Christopher A. Fausel, Pharm.D. MHA BCOP
Curriculum Vitae

Page 2

July 2008 – December 2010.

Clinical Director, Oncology Pharmacy Services
Indiana University Simon Cancer Center
Division of Hematology/Oncology, Department of Medicine
Indiana University School of Medicine
Indianapolis, Indiana.

October 1996 – July 2008.

Clinical pharmacist, Adult Hematology/Oncology/Bone Marrow Transplant
Indiana University Hospital
Clarian Health Partners
Indianapolis, Indiana.

July 1994 - September 1996.

Staff pharmacist (part time)
Samuel Stratton VA Medical Center
Albany, New York.

July 1993 - July 1994.

ASHP Pharmacy Practice Residency
Samuel Stratton VA Medical Center
Albany, New York
Mary H. Andritz Pharm.D. FASHP, Residency Director.

December 1989 - June 1993.

Pharmacy Intern
Samuel S. Stratton VA Medical Center
Albany, New York.

Licensure:

Indiana, September 1996 - present.

New York, September 1993 - present.

Christopher A. Fausel, Pharm.D. MHA BCOP
Curriculum Vitae

Page 3

Certifications:

Board Certified Oncology Pharmacist (BCOP), December, 1999. Recertification 2006, 2013.

Board Certified Pharmacotherapy Specialist (BCPS), December 1998 – December 2012. (retired)

Advanced Cardiac Life Support. American Red Cross. August 2013 – present.

Basic Life Support. American Red Cross. December 2012 - present.

Appointments:

Academic:

Indiana University School of Medicine, Department of Medicine, Division of Hematology/Oncology: Adjunct Associate Professor of Medicine. November 2000 – present.

Butler University - College of Pharmacy and Health Sciences: Assistant Adjunct Professor of Pharmacy - April 1997 – present.

Purdue University - School of Pharmacy and Pharmacal Sciences: Affiliate Assistant Professor of Clinical Pharmacy - April 1997 – present.

Professional Service:

Chairman of the Board. Hoosier Oncology Group. July 2013 – present.

National Marrow Donor Program – System Capacity Initiative – to increase pharmacist workforce in Stem Cell Transplantation September 2011 – present.

Hematology Oncology Pharmacists Association- Nominations and Awards Committee. January 2011 – December 2012. January 2015- present.

Editorial Board, Clinical Controversies. Journal of Hematology/Oncology Pharmacy. October 2010 – present.

Executive Committee, IUPUI IRB. July 2010 – present.

Academic Health Complex Pharmacy and Therapeutics Committee, Indiana University Health. July 2010 – present.

ASHP PGY2 Oncology Pharmacy Residency accreditation site reviewer. September 2008 – present.

Reviewer. Bone Marrow Transplantation. Nature publications. January 2007 – present.

Editorial Board. Guide to the management of selected adverse events associated with cancer chemotherapy, RJM Associates. June 2001 – June 2012.

Central Institutional Review Board, National Cancer Institute, Bethesda, Maryland. Scientific member. July 2000 – October 2004.

Hematology/Oncology Pharmacist Editor. Lippincott Williams and Wilkins - Springhouse Medical Publications. May 2000 – 2008.

Hoosier Oncology Group Supportive Care Committee. January 2000 – present.

Eastern Cooperative Oncology Group (ECOG). Pharmacy committee. Voting member November 1998 – present. Co-Chair, November 2001 – November 2003, Chair, November 2003 – November 2005. Multiple Myeloma Core Committee, November 2002 – present.

Scientific Review Committee, Indiana University Cancer Center, Indianapolis, Indiana. Voting member. July 1998 – present.

Institutional Review Board, Indiana University Purdue University at Indianapolis, Indianapolis, Indiana. July 1997 – present. Chair – IRB 05 and IRB 07 Emergency Committee.

Ongoing Research:

Albany C, Hanna NH, Picus J, Hauke RJ, Fausel CA, Liu Z, Brames MJ, Einhorn LH. Phase II study of fosaprepitant + 5HT3 receptor antagonists + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: Hoosier oncology group QL12-153.

Khawaja MR, Cripe LD, Schwartz JE, Kiel PJ, Fausel CA, Sayar H, Robertson MJ, Abonour R, Cornetta K, Farag S, Nelson RP Jr. Cyclophosphamide/fludarabine-based nonmyeloablative matched related/unrelated allotransplant for myelodysplasia.

Christopher A. Fausel, Pharm.D. MHA BCOP
Curriculum Vitae
Page 5

Journal Publications:

Laínez JM, Orcun S, Pekny JF, Reklaitis GV, Suvannasankha A, Fausel C, Anaissie EJ, Blau GE. Comparison of an assumption-free Bayesian approach with Optimal Sampling Schedule to a maximum a posteriori Approach for Personalizing Cyclophosphamide Dosing. *Pharmacotherapy* 2014;34:330-5.

Blau GE, Orcun S, Laínez JM, Reklaitis GV, Suvannasankha A, Fausel C, Anaissie EJ. Validation of a novel approach for dose individualization in pharmacotherapy using gabapentin in a proof of principles study. *Pharmacotherapy*. 2013 Jul;33(7):727-35.

Kiel PJ, Fausel CA, Jones KL. Testicular germ-cell tumors: A history of "If you don't cure the first time, try, try again". *J Hematol Oncol Pharm* 2012;2:85-102.

Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH. Randomized, double-blind, placebo-controlled, Phase III crossover study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors undergoing 5 day cisplatin-based chemotherapy regimen: A Hoosier Oncology Group study. *J Clin Oncol* 2012;32:3998-4003.

Ormerod A, Fausel CA, Abonour R, Kiel PJ. Observations of secondary malignancies in patients with multiple myeloma. *Clin Lymphoma Myeloma Leuk* 2012;12:113-7.

Rosenbeck LL, Kiel, PJ, Kalsekar I, Vargo C, Baute J, Sullivan CK, Wood L, Abdelqader S, Schwarz J, Srivastava S, Abonour R, Robertson MJ, Nelson RP Jr, Cornetta K, Fausel CA, Farag SS. Prophylaxis with sirolimus and tacrolimus \pm antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation. *Biol Blood Marrow Transplant* 2011;17:916-22.

Greisl NJ, Fausel CA. The Evolution of Tyrosine Kinase Inhibitor Therapy: Improving Outcomes in Patients with Newly Diagnosed Chronic Myelogenous Leukemia. *J Hematol Oncol Pharm* 2011; 1(4) 25-32.

Fausel CA. Iron chelation therapy in myelodysplastic syndrome. *Am J Health Syst Pharm*. 2010 Apr;67(7 Suppl 2):S10-4.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.